Princeton - 22 hours ago

Attend this fireside chat to hear two experts—Debra Wentz, PhD, and Dr. Dan Iosifescu—discuss their perspectives on addressing mental health problems in a constantly evolving world. Debra L. Wentz, PhD, is the President and Chief Executive Officer of the New Jersey Association of Mental Health and Addiction Agencies (NJAMHAA) and Executive Director of the New Jersey Mental Health Institute. NJAMHAA represents 153 hospital-based and freestanding behavioral healthcare provider organizations that serve more than 500,000 children and adults annually. Dr. Wentz holds numerous Board and committee positions and appointments on the state and national levels, including several at the National Council for Behavioral Health, and the New Jersey Governor’s Council on Mental Health Stigma. She served on Governor Phil Murphy’s Health Advisory Transition Committee and on the Transition Teams of other previous governors. Under Dr. Wentz’s leadership, NJAMHAA received the Advocacy Leadership Award for Organizational Excellence from the National Council for Behavioral Health in June 2020. In 2019, Dr. Wentz was recognized by ROI-NJ with a Champions of the C-Suite (CEOs of the Year) award and by NJBIZ with an ICON Honors award. A sought after expert on mental health and substance use issues for the media and conferences, Dr. Wentz has been interviewed frequently on local, state, national and even international television and radio programs, and is regularly cited and featured in print publications. Dr. Wentz earned a Doctoral degree from University of Paris, Paris, F a second PhD and MA degree from the University of Conne and an Executive MBA from the Alternative Careers Program of the Wharton Business School, University of Pennsylvania. She completed undergraduate work at Goucher College, Maryland. She is bilingual in French and English. Dr. Dan Iosifescu is Professor of Psychiatry at the New York University Grossman School of Medicine and Director of the Clinical Research Division at the Nathan Kline Institute. His research is focused on novel pharmacological treatments (such as ketamine and other glutamatergic drugs) and devices (such as photobiomodulation with near infrared light and novel forms of magnetic stimulation) for patients with severe mood (major depression and bipolar disorder) and cognitive disorders (Alzheimer’s disease). In his research Dr. Iosifescu uses neuroimaging (MRI, MRS, PET) and neurophysiology (quantitative EEG) techniques to evaluate structural, biochemical, and functional brain abnormalities in mood and cognitive disorders, and their impact on clinical treatment.

Latest News

Hashtags:   

Breaking

 | 

Silence

 | 

Fireside

 | 

Mental

 | 

Health

 | 

Challenges

 | 

Changing

 | 

World

 | 

Sources